MBP and B-cell non-Hodgkin lymphoma: By using the Tg4 TCR transgenic system [33] to generate effector T cells, iTregs, in vivo tolerized T cells and T cells acutely tolerized by treatment with UCB9608 we can activate the T cells with the same PL8 B cell lymphoma APCs presenting the same MBP Ac1-9[4Y] agonist peptide at the same concentration of 10 μg/mL.